Literature summary for 1.13.11.31 extracted from

Miyata, J.; Yokokura, Y.; Moro, K.; Arai, H.; Fukunaga, K.; Arita, M.
12/15-Lipoxygenase regulates IL-33-induced eosinophilic airway inflammation in mice (2021), Front. Immunol., 12, 687192 .

Search for more literature for 1.13.11.31

Application

Application	Comment	Organism
medicine	application of 14(S)-hydroxy docosahexaenoic acid suppresses IL-33-mediated eosinophilic inflammation in 12/15-LOX-deficient mice. 14(S)-hydroxy docosahexaenoic acid and 10(S),17(S)-dihydroxy docosahexaenoic acid markedly attenuate ILC2 proliferation and cytokine production at micromolar concentration in vitro. Maresin 1 (MaR1) and resolvin D1 (RvD1), 12/15-LOX-derived specialized proresolving mediators (SPMs), inhibited cytokine production of ILC2s at nanomolar concentration	Mus musculus

Organism

Organism	UniProt	Comment	Textmining
Mus musculus	P39654	cf. EC 1.13.11.33	-

Synonyms

Synonyms	Comment	Organism
12/15-LOX	-	Mus musculus
Alox15	-	Mus musculus

General Information

General Information	Comment	Organism
physiological function	12/15-LOX-deficient mice display augmented IL-33-induced lung inflammation, characterized by an increased number of infiltrated eosinophils and group 2 innate lymphoid cells in the airway. The levels of a series of 12/15-LOX-derived metabolites are significantly decreased, and application of 14(S)-hydroxy docosahexaenoic acid suppresses IL-33-mediated eosinophilic inflammation in 12/15-LOX-deficient mice. 14(S)-hydroxy docosahexaenoic acid and 10(S),17(S)-dihydroxy docosahexaenoic acid markedly attenuate ILC2 proliferation and cytokine production at micromolar concentration in vitro	Mus musculus

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)